User profiles for "author:Amalia Gastaldelli"
Amalia GastaldelliInstitute of Clinical Physiology, CNR Verified email at cnr.it Cited by 39004 |
[HTML][HTML] Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease
Non-alcoholic fatty liver disease is marked by hepatic fat accumulation not due to alcohol
abuse. Several studies have demonstrated that NAFLD is associated with insulin resistance …
abuse. Several studies have demonstrated that NAFLD is associated with insulin resistance …
[PDF][PDF] Why does obesity cause diabetes?
The accumulation of an excessive amount of body fat can cause type 2 diabetes, and the
risk of type 2 diabetes increases linearly with an increase in body mass index. Accordingly …
risk of type 2 diabetes increases linearly with an increase in body mass index. Accordingly …
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide and is often associated with aspects of metabolic syndrome. Despite its …
worldwide and is often associated with aspects of metabolic syndrome. Despite its …
[HTML][HTML] A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
R Belfort, SA Harrison, K Brown… - … England Journal of …, 2006 - Mass Medical Soc
Background No pharmacologic therapy has conclusively proved to be effective for the
treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance …
treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance …
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
A Gastaldelli, K Cusi, M Pettiti, J Hardies, Y Miyazaki… - Gastroenterology, 2007 - Elsevier
Background & Aims: Abdominal fat accumulation (visceral/hepatic) has been associated
with hepatic insulin resistance (IR) in obesity and type 2 diabetes (T2DM). We examined the …
with hepatic insulin resistance (IR) in obesity and type 2 diabetes (T2DM). We examined the …
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes
S Kashyap, R Belfort, A Gastaldelli, T Pratipanawatr… - Diabetes, 2003 - Am Diabetes Assoc
Acute elevations in free fatty acids (FFAs) stimulate insulin secretion, but prolonged lipid
exposure impairs β-cell function in both in vitro studies and in vivo animal studies. In …
exposure impairs β-cell function in both in vitro studies and in vivo animal studies. In …
β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis
E Ferrannini, A Gastaldelli, Y Miyazaki… - The Journal of …, 2005 - academic.oup.com
The nature of the progressive β-cell failure occurring as normal glucose tolerant (NGT)
individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured …
individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured …
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity
E Bugianesi, U Pagotto, R Manini… - The journal of …, 2005 - academic.oup.com
Plasma levels of adiponectin are decreased in patients with nonalcoholic fatty liver disease
(NAFLD), but the relationship among plasma adiponectin, insulin sensitivity, and histological …
(NAFLD), but the relationship among plasma adiponectin, insulin sensitivity, and histological …
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the …
A Gastaldelli, K Cusi, LF Landó, R Bray… - The lancet Diabetes & …, 2022 - thelancet.com
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH), a cause of cirrhosis and hepatocellular carcinoma, is
characterized by fatty infiltration of the liver, inflammation, hepatocellular damage and …
characterized by fatty infiltration of the liver, inflammation, hepatocellular damage and …